JP5786178B2 - Ｔｔｋペプチドおよびそれを含むワクチン - Google Patents

Ｔｔｋペプチドおよびそれを含むワクチン Download PDF

Info

Publication number
JP5786178B2
JP5786178B2 JP2011548451A JP2011548451A JP5786178B2 JP 5786178 B2 JP5786178 B2 JP 5786178B2 JP 2011548451 A JP2011548451 A JP 2011548451A JP 2011548451 A JP2011548451 A JP 2011548451A JP 5786178 B2 JP5786178 B2 JP 5786178B2
Authority
JP
Japan
Prior art keywords
peptide
cancer
ttk
ctl
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011548451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012526519A (ja
JP2012526519A5 (enExample
Inventor
中村　祐輔
祐輔 中村
卓也 角田
卓也 角田
龍司 大沢
龍司 大沢
祥子 吉村
祥子 吉村
朝久 渡辺
朝久 渡辺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2012526519A publication Critical patent/JP2012526519A/ja
Publication of JP2012526519A5 publication Critical patent/JP2012526519A5/ja
Application granted granted Critical
Publication of JP5786178B2 publication Critical patent/JP5786178B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011548451A 2009-05-11 2010-05-10 Ｔｔｋペプチドおよびそれを含むワクチン Expired - Fee Related JP5786178B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21601709P 2009-05-11 2009-05-11
US61/216,017 2009-05-11
PCT/JP2010/003166 WO2010131452A1 (en) 2009-05-11 2010-05-10 Ttk peptides and vaccines including the same

Publications (3)

Publication Number Publication Date
JP2012526519A JP2012526519A (ja) 2012-11-01
JP2012526519A5 JP2012526519A5 (enExample) 2013-06-27
JP5786178B2 true JP5786178B2 (ja) 2015-09-30

Family

ID=43084837

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011548451A Expired - Fee Related JP5786178B2 (ja) 2009-05-11 2010-05-10 Ｔｔｋペプチドおよびそれを含むワクチン

Country Status (13)

Country Link
US (1) US8530430B2 (enExample)
EP (1) EP2430039A4 (enExample)
JP (1) JP5786178B2 (enExample)
KR (1) KR20120029394A (enExample)
CN (1) CN102459314B (enExample)
AU (1) AU2010248702A1 (enExample)
BR (1) BRPI1013938A2 (enExample)
CA (1) CA2761393A1 (enExample)
MX (1) MX2011012013A (enExample)
RU (1) RU2531348C2 (enExample)
SG (1) SG175998A1 (enExample)
TW (1) TW201102081A (enExample)
WO (1) WO2010131452A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6283861B2 (ja) 2012-09-11 2018-02-28 オンコセラピー・サイエンス株式会社 Ｕｂｅ２ｔペプチドおよびそれを含むワクチン
WO2018090257A1 (zh) * 2016-11-16 2018-05-24 深圳华大基因研究院 多肽及其应用
WO2018098636A1 (zh) * 2016-11-29 2018-06-07 深圳华大基因研究院 多肽及其应用
BR112020000590A2 (pt) * 2017-07-12 2020-07-14 Nouscom Ag método de seleção de uma coleção, métodos para determinar as sequências de aminoácidos e para produzir uma cvp ou uma coleção de ácidos nucleicos, cvp, coleções de peptídeos de vacina, de ácidos nucleicos, de um ou mais vetores de expressão e coleção de vetores de expressão
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187548B1 (en) * 1993-05-23 2001-02-13 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods using human calcium sensor protein, fragments thereof and DNA encoding same
US20030045491A1 (en) 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
CN100578227C (zh) 2001-02-21 2010-01-06 诺华疫苗和诊断公司 用于诊断和作为癌症治疗靶标的ttk
US7501243B2 (en) * 2001-02-21 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Detection of colon or breast cancer by measuring TTK polypeptide expression
CA2444691A1 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2003210393A1 (en) * 2002-02-27 2003-09-09 Michael Rik Frans Brands A data integration and knowledge management solution
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
DE602004015064D1 (de) 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
WO2004070062A2 (en) 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
EP1670955A2 (en) 2003-09-22 2006-06-21 Rosetta Inpharmatics LLC. Synthetic lethal screen using rna interference
JP4721903B2 (ja) * 2004-01-29 2011-07-13 大日本住友製薬株式会社 新規腫瘍抗原蛋白質及びその利用
GB0426393D0 (en) 2004-12-01 2005-01-05 Cancer Rec Tech Ltd Materials and methods relating to modulators of spindle checkpoint kinases
JP5139811B2 (ja) 2004-12-08 2013-02-06 アベンティス・ファーマスーティカルズ・インコーポレイテツド ドセタキセル耐性または感受性の測定方法
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
DK2325306T3 (en) 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
EP1907582B1 (en) 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
EP2305811A1 (en) 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
EP2468887A1 (en) 2006-12-13 2012-06-27 Oncotherapy Science, Inc. TTK as tumor marker and therapeutic target for lung cancer
TWI494319B (zh) * 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
US8492356B2 (en) 2007-12-21 2013-07-23 University Health Network Methods of inhibiting tumor growth using TTK antagonists
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
KR20120029394A (ko) 2012-03-26
RU2011150283A (ru) 2013-06-20
CN102459314A (zh) 2012-05-16
RU2531348C2 (ru) 2014-10-20
JP2012526519A (ja) 2012-11-01
CN102459314B (zh) 2016-01-20
WO2010131452A1 (en) 2010-11-18
MX2011012013A (es) 2012-02-23
US8530430B2 (en) 2013-09-10
US20120135020A1 (en) 2012-05-31
BRPI1013938A2 (pt) 2019-09-24
CA2761393A1 (en) 2010-11-18
EP2430039A4 (en) 2012-12-05
EP2430039A1 (en) 2012-03-21
TW201102081A (en) 2011-01-16
SG175998A1 (en) 2011-12-29
AU2010248702A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
JP6349560B2 (ja) Ｔｏｐｋペプチドおよびそれを含むワクチン
JP6295491B2 (ja) Ｋｎｔｃ２ペプチドおよびそれを含むワクチン
JP5799394B2 (ja) Ｎｅｉｌ３ペプチドおよびそれを含むワクチン
JP5884104B2 (ja) 改変ｍｅｌｋペプチドおよびそれを含むワクチン
JP2013523084A (ja) Ｃｄｃａ５ペプチドおよびそれを含むワクチン
JP6283861B2 (ja) Ｕｂｅ２ｔペプチドおよびそれを含むワクチン
JP5564730B2 (ja) Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン
JP2014519311A (ja) Ｓｅｍａ５ｂペプチドおよびそれを含むワクチン
JP2016222676A (ja) Ｔｏｍｍ３４ペプチドおよびそれを含むワクチン
US8530430B2 (en) TTK peptides and vaccines including the same
JP5838482B2 (ja) Ｈｊｕｒｐペプチドおよびそれを含むワクチン
JP2012519470A (ja) Ｖａｎｇｌ１ペプチドおよびそれを含むワクチン
JP5816965B2 (ja) Ｅｃｔ２ペプチドおよびそれを含むワクチン
JP5728759B2 (ja) Ｃ６ｏｒｆ１６７ペプチドおよびそれを含むワクチン
WO2012032764A1 (en) Ttll4 peptides and vaccines containing the same
JP2013513549A (ja) Ｔｍｅｍ２２ペプチドおよびそれを含むワクチン
JP2013512659A (ja) Ｍｙｂｌ２ペプチドおよびそれを含むワクチン
JP2016502499A (ja) Ｓｅｍａ５ｂペプチドおよびそれを含むワクチン
JP2014500001A (ja) Ｃ１８ｏｒｆ５４ペプチドおよびそれを含むワクチン
JP2014504146A (ja) Ｗｄｈｄ１ペプチドおよびそれを含むワクチン
JP2013523083A (ja) Ｃｌｕａｐ１ペプチドおよびそれを含むワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141113

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150623

R150 Certificate of patent or registration of utility model

Ref document number: 5786178

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees